Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145249
Status:
COMPLETED
Last Update Posted:
2012-05-16
First Post:
2005-09-02
Brief Title:
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine the effectiveness and safety of a combination treatment for cryptococcal meningitis a fungal infection common in persons with acquired immune deficiency syndrome AIDS in the developing world The standard initial treatment includes two medications amphotericin B for 2 weeks followed by 8 weeks of fluconazole This study will look at whether study participants recover more quickly and have fewer side effects if they are given both drugs at the same time for 2 weeks followed by 8 weeks of fluconazole as compared to the standard treatment Participants will be followed for approximately 6 months from the time they are enrolled into the study
Detailed Description:
This study is designed to address the need for more effective antifungal therapy for cryptococcal meningitis This is a prospective randomized open-label multicenter phase II clinical trial of combination therapy for the treatment of acute cryptococcal meningitis in HIV-positive subjects The primary study objectives will be to assess the safety and tolerability of the study drug regimens and to determine whether the safety and efficacy of combination therapy supports development of a phase III trial of combination therapy and if so to select the most appropriate dose of fluconazole plus amphotericin B based on safety and efficacy to be evaluated in a subsequent phase III trial Secondary study objectives include comparing the efficacy of the study drug treatments at 2 6 and 10 weeks Days 14 42 and 70 comparing the findings on detailed neurological examination between study arms at baseline and 2 6 10 and 24 weeks 6 months assessing the proportion of subjects in each study arm that are alive at 6 months after initiation of study therapy describing the effects of baseline clinical neurological and mycological characteristics on mycological failure at 2 and 10 weeks measuring time to cerebrospinal fluid CSF culture negatively for each study arm assessing the length of hospitalization in the treatment groups as a surrogate of cost efficacy assessing the incidence of immune reconstitution inflammatory syndrome among all subjects receiving highly active antiretroviral therapy HAART and examining antifungal susceptibility of all cryptococcal isolates Study participants will include 150 subjects ages 13 and older Subjects will be randomly assigned to 1 of 3 treatment arms including 1 standard therapy and 2 investigational arms The standard treatment arm will include amphotericin B 07 mgkg IV for 14 days followed by 8 weeks 56 days of fluconazole at 400 mgday orally The 2 investigational arms will include daily amphotericin B 07 mgkg IV and the randomized dose of fluconazole 400 mgday or 800 mgday for the first 14 day then the randomized dose of fluconazole at 400 mgday or 800 mgday respectively for an additional 8 weeks 56 days At the completion of study therapy all subjects will receive chronic suppressive therapy with oral fluconazole at a dose of at least 200 mgday The safety endpoints are considered to be the primary endpoints for this study The safety assessment for each treatment arm will end at study day 100 for each subject The key safety endpoint will be the incidence of adverse experiences of grade 3-5 total and attributed to the treatment regimens The primary safety endpoint will examine the incidence of grade 3-5 adverse experiences that are definitely or probably related to study drugs while secondary analysis will include grade 3-5 adverse experiences that are definitely probably or possibly related to study drugs Another secondary safety endpoint will be the number of dose-limiting toxicities attributed to the treatment regimens Key efficacy endpoint treatment success will be a composite of the following 3 mycologic and clinical measures after 14 42 and 70 days of therapy CSF culture conversion neurologically stable or improved and alive Other secondary efficacy endpoints that will be evaluated descriptively are CSF culture conversion at multiple time points all-cause mortality length of hospitalization and incidence of immune reconstitution inflammatory syndrome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BAMSG 3-01 | None | None | None |